American State Bank (Iowa)’s Alexion Pharmaceuticals ALXN Stock Holding History

American State Bank (Iowa)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$73.5K	–	298
2021 Q2	$73.5K	Hold	400	–	–	0.06%	167
2021 Q1	$61.2K	Hold	400	–	–	0.05%	179
2020 Q4	$62.5K	Buy	+400	New	+$51.4K	0.06%	168

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

American State Bank (Iowa)'s ALXN Position: Q3 2021 in Review

American State Bank (Iowa) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 400 shares — an estimated $73.5K sold.

American State Bank (Iowa) first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $73.5K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

American State Bank (Iowa) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
American State Bank (Iowa) sold 400 Alexion Pharmaceuticals shares in Q3 2021, an estimated $73.5K.
American State Bank (Iowa) first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
American State Bank (Iowa)'s Alexion Pharmaceuticals position peaked at $73.5K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on American State Bank (Iowa)'s 13F filing for Q3 2021, filed 14 Apr 2026.